TY - JOUR
T1 - Bis(propyl)-cognitin potentiates rehabilitation of treadmill exercise after a transient focal cerebral ischemia, possibly via inhibiting NMDA receptor and regulating VEGF expression
AU - Ke, Zheng
AU - Hu, Shengquan
AU - Cui, Wei
AU - Sun, Jing
AU - Zhang, Shaojie
AU - Mak, Shinghung
AU - Wang, Jiajun
AU - Tang, Jing
AU - Pang, Yuanping
AU - Han, Yifan
AU - Tong, Kaiyu
N1 - Funding Information:
This work was supported by the research grants from General Research Fund ( 14204315 ), PolyU ( G-YBGQ , G-YZ95 ), the Research Grant Council of Hong Kong ( 15101014 ), ITSP-Guangdong–Hong Kong Technology Cooperation Funding Scheme ( GHP/012/16GD ), Shenzhen Basic Research Program ( JCYJ20160331141459373 ) and the National Natural Science Foundation of China (No. 21576199 ). We sincerely thank Ms. Josephine Leung for proofreading our manuscript.
Publisher Copyright:
© 2019
PY - 2019/9
Y1 - 2019/9
N2 - Combination therapies may have greater efficacy compared with monotherapy in treating stroke. We investigated the molecular mechanisms by which the combination of bis(propyl)-cognitin, an uncompetitive antagonist of NMDA receptor, and treadmill exercise promote rehabilitation after ischemic stroke. Rats were distributed into 3 treatment groups: infarct/bis(propyl)-cognitin(drug only group, DO); infarct/treadmill exercise(exercise only group, EO); infarct/bis(propyl)-cognitin + treadmill exercise (drug + exercise group, DE). The DE group had further separated to 3 sub-groups to investigate the effects achieved by different time for drug administration (60 min before stroke (DE-60 m), 15 min (DE+15 m) and 60 min (DE+60 m) after stroke). Although all infarct groups improved over time, the combination of bis(propyl)-cognitin and treadmill exercise effectively enhanced motor recovery during 14-day intervention. Early drug intervention has a best recovery result, the DE+15 m group with drug intervention at 15-min after stroke had better motor recovery than DE+60 m, DO, EO and control groups. Both bis(propyl)-cognitin and treadmill exercise significantly elevated brain VEGF expression and decreased brain infarct volume at 14 day post-ischemia. Our study reveals that bis(propyl)-cognitin potentiated rehabilitation of treadmill exercise after ischemic stroke, possibly via regulating brain VEGF expression, indicating that the combination of NMDA receptor antagonists and exercise might be useful for stroke rehabilitation.
AB - Combination therapies may have greater efficacy compared with monotherapy in treating stroke. We investigated the molecular mechanisms by which the combination of bis(propyl)-cognitin, an uncompetitive antagonist of NMDA receptor, and treadmill exercise promote rehabilitation after ischemic stroke. Rats were distributed into 3 treatment groups: infarct/bis(propyl)-cognitin(drug only group, DO); infarct/treadmill exercise(exercise only group, EO); infarct/bis(propyl)-cognitin + treadmill exercise (drug + exercise group, DE). The DE group had further separated to 3 sub-groups to investigate the effects achieved by different time for drug administration (60 min before stroke (DE-60 m), 15 min (DE+15 m) and 60 min (DE+60 m) after stroke). Although all infarct groups improved over time, the combination of bis(propyl)-cognitin and treadmill exercise effectively enhanced motor recovery during 14-day intervention. Early drug intervention has a best recovery result, the DE+15 m group with drug intervention at 15-min after stroke had better motor recovery than DE+60 m, DO, EO and control groups. Both bis(propyl)-cognitin and treadmill exercise significantly elevated brain VEGF expression and decreased brain infarct volume at 14 day post-ischemia. Our study reveals that bis(propyl)-cognitin potentiated rehabilitation of treadmill exercise after ischemic stroke, possibly via regulating brain VEGF expression, indicating that the combination of NMDA receptor antagonists and exercise might be useful for stroke rehabilitation.
KW - Exercise
KW - Ischemia
KW - Motor recovery
KW - Stroke
KW - VEGF
KW - bis(propyl)-cognitin
UR - http://www.scopus.com/inward/record.url?scp=85065026695&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065026695&partnerID=8YFLogxK
U2 - 10.1016/j.neuint.2019.04.016
DO - 10.1016/j.neuint.2019.04.016
M3 - Article
C2 - 31034915
AN - SCOPUS:85065026695
SN - 0197-0186
VL - 128
SP - 143
EP - 153
JO - Neurochemistry International
JF - Neurochemistry International
ER -